Search Results - "ELKABETS, Moshe"

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy by Scaltriti, Maurizio, Elkabets, Moshe, Baselga, José

“…AXL is a tyrosine kinase membrane receptor that signals via PI3K, MAPK, and protein kinase C (PKC), among other pathways. AXL has oncogenic potential and…”
Get full text

Probing antibody surface density and analyte antigen incubation time as dominant parameters influencing the antibody-antigen recognition events of a non-faradaic and diffusion-restricted electrochemical immunosensor by Zorea, Jonathan, Shukla, Rajendra P., Elkabets, Moshe, Ben-Yoav, Hadar

“…Electrochemical sensors based on antibody-antigen recognition events are commonly used for the rapid, label-free, and sensitive detection of various analytes…”
Get full text

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D by Toska, Eneda, Osmanbeyoglu, Hatice U., Castel, Pau, Chan, Carmen, Hendrickson, Ronald C., Elkabets, Moshe, Dickler, Maura N., Scaltriti, Maurizio, Leslie, Christina S., Armstrong, Scott A., Baselga, José

“…Activating mutations in PIK3CA, the gene encoding phosphoinositide-(3)-kinase α (PI3Kα), are frequently found in estrogen receptor (ER)–positive breast cancer…”
Get full text

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair by Zhang, Shaolu, Peng, Xin, Li, Xiaofei, Liu, Hongyan, Zhao, Baoquan, Elkabets, Moshe, Liu, Yao, Wang, Wei, Wang, Ran, Zhong, Yuxu, Kong, Dexin

“…PARP inhibitors have been approved for the therapy of cancers with homologous recombination (HR) deficiency based on the concept of “synthetic lethality”…”
Get full text

José Baselga M.D., Ph.D. (1959-2021) leading cancer researcher and oncologist by Elkabets, Moshe, Blandino, Giovanni

“…In 1989, at the age of 30, José moved to MSK to work in the clinic with Larry Norton and in the laboratory with John Mendelsohn to investigate the anti-tumor…”
Get full text

Potential oncogenic roles of mutant-p53-derived exosomes in the tumor–host interaction of head and neck cancers by Azulay, Etti Ester, Cooks, Tomer, Elkabets, Moshe

“…The wide-ranging collection of malignancies arising at the upper aerodigestive tract is categorized as head and neck cancer (HNC), the sixth most prevalent…”
Get full text

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment by Shamay, Yosi, Elkabets, Moshe, Li, Hongyan, Shah, Janki, Brook, Samuel, Wang, Feng, Adler, Keren, Baut, Emily, Scaltriti, Maurizio, Jena, Prakrit V, Gardner, Eric E, Poirier, John T, Rudin, Charles M, Baselga, José, Haimovitz-Friedman, Adriana, Heller, Daniel A

“…Disseminated tumors are poorly accessible to nanoscale drug delivery systems because of the vascular barrier, which attenuates extravasation at the tumor site…”
Get more information

Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis by Novoplansky, Ofra, Jagadeeshan, Sankar, Regev, Ohad, Menashe, Idan, Elkabets, Moshe

“…In light of the development of RAS inhibitors, a reliable assessment of the prevalence of RAS mutations and their correlation with the clinical features of…”
Get full text

Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy by Tzuri, Noam, Yegodayev, Ksenia M., Novoplansky, Ofra, Elkabets, Moshe, Aharoni, Amir, Papo, Niv

“…Cancer progression is enhanced by the interaction of programmed death-ligand 1 (PDL1), which is associated with inhibition of the immune response against…”
Get full text

Gene Expression and Drug Sensitivity Analysis of Mitochondrial Chaperones Reveals That HSPD1 and TRAP1 Expression Correlates with Sensitivity to Inhibitors of DNA Replication and Mitosis by Badarni, Mai, Gabbay, Shani, Elkabets, Moshe, Rotblat, Barak

“…Mitochondria-critical metabolic hubs in eukaryotic cells-are involved in a wide range of cellular functions, including differentiation, proliferation, and…”
Get full text

57 Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer by Elkabets, Moshe, Kaufman, Bar, Porgador, Angel

“…BackgroundAccurate predictive biomarkers of response to immune checkpoint inhibitors (ICIs) are required for better stratifying patients with cancer to ICI…”
Get full text

The Potential of PIP3 in Enhancing Wound Healing by Blitsman, Yossi, Hollander, Etili, Benafsha, Chen, Yegodayev, Ksenia M, Hadad, Uzi, Goldbart, Riki, Traitel, Tamar, Rudich, Assaf, Elkabets, Moshe, Kost, Joseph

“…Given the role of phosphatidylinositol 3,4,5-trisphosphate (PIP3) in modulating cellular processes such as proliferation, survival, and migration, we…”
Get full text

TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer by Zorea, Jonathan, Motro, Yair, Mazor, Roei D, Carmi, Yifat Koren, Shulman, Ziv, Mahajna, Jamal, Moran-Gilad, Jacob, Elkabets, Moshe

“…Ovarian cancer (OC) is known for exhibiting low response rates to immune checkpoint inhibitors that activate T cells. However, immunotherapies that activate B…”
Get full text

Tumor Cell-Associated IL-1α Affects Breast Cancer Progression and Metastasis in Mice through Manipulation of the Tumor Immune Microenvironment by Krishnamohan, Mathumathi, Kaplanov, Irena, Maudi-Boker, Sapir, Yousef, Muhammad, Machluf-Katz, Noy, Cohen, Idan, Elkabets, Moshe, Titus, Jaison, Bersudsky, Marina, Apte, Ron N, Voronov, Elena, Braiman, Alex

“…IL-1α is a dual function cytokine that affects inflammatory and immune responses and plays a pivotal role in cancer. The effects of intracellular IL-1α on the…”
Get full text

The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment by Greenshpan, Yariv, Sharabi, Omri, Yegodayev, Ksenia M, Novoplansky, Ofra, Elkabets, Moshe, Gazit, Roi, Porgador, Angel

“…Harnessing immune effector cells to benefit cancer patients is becoming more and more prevalent in recent years. However, the increasing number of different…”
Get full text

IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer by Zorea, Jonatan, Prasad, Manu, Cohen, Limor, Li, Nan, Schefzik, Roman, Ghosh, Susmita, Rotblat, Barak, Brors, Benedikt, Elkabets, Moshe

“…Genomic alterations (GA) in PIK3CA leads to the hyper-activation of the phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) pathway in more than 20% of…”
Get full text

A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation by Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Zhang, Shaolu, Cohen, Limor, Huang, Shengfan, Fan, Jindian, Chen, Xi, Liu, Shanshan, Wang, Yongzhe, Wang, Kailin, Isoyama, Sho, Dan, Shingo, Wang, Feng, Zhang, Zhe, Elkabets, Moshe, Kong, Dexin

“…Phosphoinositide 3-kinases (PI3Ks) are critical regulators of diverse cellular functions and have emerged as promising targets in cancer therapy. Despite…”
Get full text

Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin by Sarfati, Gadi, Dvir, Tal, Elkabets, Moshe, Apte, Ron N, Cohen, Smadar

“…Abstract Effective therapy for disseminated metastatic cancer is currently impossible because of low drug accumulation in target sites. Here, we aimed to…”
Get full text

Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis by Carmi, Yaron, Rinott, Gal, Dotan, Shahar, Elkabets, Moshe, Rider, Peleg, Voronov, Elena, Apte, Ron N

“…Inflammatory cytokines modulate immune responses in the tumor microenvironment during progression/metastasis. In this study, we have assessed the role of IL-1…”
Get full text

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer by Yegodayev, Ksenia M, Novoplansky, Ofra, Golden, Artemiy, Prasad, Manu, Levin, Liron, Jagadeeshan, Sankar, Zorea, Jonathan, Dimitstein, Orr, Joshua, Ben-Zion, Cohen, Limor, Khrameeva, Ekaterina, Elkabets, Moshe

“…Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against the epidermal growth factor receptor. Such therapy resistance is known…”
Get full text